A Next-Generation RNA Therapy Targets Telomere Disorders

Akihiro Ko, CEO Elixirgen Therapeutics, discusses telomere biology disorders, the company’s self-replicating RNA therapies, and the advantages this new therapeutic approach offers over more traditional mRNA therapies.